Principal Financial Group Inc. grew its stake in shares of PetMed Express, Inc. (NASDAQ:PETS) by 4.0% during the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 173,219 shares of the company’s stock after purchasing an additional 6,741 shares during the quarter. Principal Financial Group Inc. owned about 0.85% of PetMed Express worth $7,033,000 at the end of the most recent quarter.

Other large investors also recently bought and sold shares of the company. Acadian Asset Management LLC bought a new position in shares of PetMed Express during the 2nd quarter worth approximately $18,691,000. Oaktop Capital Management II L.P. bought a new position in shares of PetMed Express during the 2nd quarter worth approximately $15,171,000. Renaissance Technologies LLC boosted its stake in shares of PetMed Express by 11.8% during the 1st quarter. Renaissance Technologies LLC now owns 1,786,315 shares of the company’s stock worth $35,976,000 after acquiring an additional 188,615 shares during the period. Dimensional Fund Advisors LP boosted its stake in shares of PetMed Express by 24.0% during the 1st quarter. Dimensional Fund Advisors LP now owns 794,669 shares of the company’s stock worth $16,005,000 after acquiring an additional 153,709 shares during the period. Finally, Prudential Financial Inc. boosted its stake in shares of PetMed Express by 261.0% during the 2nd quarter. Prudential Financial Inc. now owns 126,294 shares of the company’s stock worth $5,127,000 after acquiring an additional 91,310 shares during the period. 78.91% of the stock is currently owned by hedge funds and other institutional investors.

PETS has been the subject of several research analyst reports. ValuEngine upgraded PetMed Express from a “hold” rating to a “buy” rating in a research note on Friday, September 1st. Sidoti upgraded PetMed Express from a “neutral” rating to a “buy” rating and set a $47.00 target price for the company in a research note on Thursday, August 24th. BidaskClub downgraded PetMed Express from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, August 22nd. Northcoast Research upgraded PetMed Express from a “neutral” rating to a “buy” rating and set a $54.00 target price for the company in a research note on Monday, July 24th. Finally, Zacks Investment Research downgraded PetMed Express from a “strong-buy” rating to a “hold” rating in a research note on Monday, September 25th. Three research analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. PetMed Express presently has an average rating of “Buy” and a consensus target price of $44.75.

Shares of PetMed Express, Inc. (NASDAQ:PETS) opened at 33.15 on Friday. The company has a 50-day moving average price of $40.97 and a 200 day moving average price of $33.60. The company has a market capitalization of $672.68 million, a P/E ratio of 25.50 and a beta of 1.03. PetMed Express, Inc. has a 1-year low of $18.90 and a 1-year high of $50.90.

PetMed Express (NASDAQ:PETS) last posted its quarterly earnings results on Monday, July 24th. The company reported $0.45 EPS for the quarter, topping the Zacks’ consensus estimate of $0.38 by $0.07. PetMed Express had a return on equity of 28.67% and a net margin of 10.34%. The firm had revenue of $79.66 million during the quarter, compared to analyst estimates of $77.32 million. During the same period last year, the company earned $0.32 earnings per share. The business’s revenue for the quarter was up 9.9% on a year-over-year basis. Equities research analysts anticipate that PetMed Express, Inc. will post $1.44 EPS for the current year.

In other news, Director Robert C. Schweitzer sold 5,000 shares of the firm’s stock in a transaction on Thursday, July 27th. The stock was sold at an average price of $48.60, for a total value of $243,000.00. Following the completion of the transaction, the director now directly owns 83,834 shares of the company’s stock, valued at $4,074,332.40. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Robert C. Schweitzer sold 2,500 shares of the firm’s stock in a transaction on Tuesday, August 1st. The stock was sold at an average price of $49.18, for a total value of $122,950.00. Following the completion of the transaction, the director now directly owns 88,834 shares of the company’s stock, valued at $4,368,856.12. The disclosure for this sale can be found here. Insiders sold 19,333 shares of company stock valued at $949,730 over the last ninety days. Corporate insiders own 4.00% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “PetMed Express, Inc. (PETS) Holdings Lifted by Principal Financial Group Inc.” was originally published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this piece on another site, it was copied illegally and republished in violation of U.S. and international copyright laws. The correct version of this piece can be read at https://www.thecerbatgem.com/2017/10/01/petmed-express-inc-pets-holdings-lifted-by-principal-financial-group-inc.html.

PetMed Express Profile

PetMed Express, Inc (PetMed Express), doing business as 1800PetMeds, is a pet pharmacy. The Company markets prescription and non-prescription pet medications, and other health products for dogs and cats, direct to the consumer. It offers a selection of products for dogs and cats. Its product line contains approximately 3,000 stock keeping units (SKUS) of pet medications, health products and supplies.

Want to see what other hedge funds are holding PETS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for PetMed Express, Inc. (NASDAQ:PETS).

Institutional Ownership by Quarter for PetMed Express (NASDAQ:PETS)

Receive News & Stock Ratings for PetMed Express Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PetMed Express Inc. and related stocks with our FREE daily email newsletter.